News
Nvidia Releases Over Two Dozen Healthcare AI Microservices
AI chip giant Nvidia has released 25 new microservices aimed at healthcare providers looking to integrate AI into their existing systems.
Announced at Nvidia's GTC conference this week, the microservices can essentially dock onto a healthcare organization's current applications, whether they're in the cloud or on-premises, and add generative AI capabilities.
"The microservices...can accelerate transformation for healthcare companies as generative AI introduces numerous opportunities for pharmaceutical companies, doctors and hospitals," Nvidia said in a Monday press release.
The new microservices are part of the Nvidia Inference Microservice (or NIM) platform, also announced at GTC. Nvidia describes NIM as "a set of optimized cloud-native microservices designed to shorten time-to-market and simplify deployment of generative AI models anywhere, across cloud, data center, and GPU-accelerated workstations."
Healthcare-related microservices available through NIM include:
- MolMIM: Generative chemistry
- ESMFold: Protein structure predictions
- DiffDock: Drug molecule interaction predictions
- VISTA 3D: 3-D segmentation model creation
- Universal DeepVariant: Variant calling in genomic analysis workflows
Nvidia's broader healthcare AI platform, BioNeMo, also announced some upgrades at GTC this week, primarily in the form of new foundation models. They include:
- DNABERT: DNA mutation predictions
- scBERT: Predictions based on single-cell RNA sequencing
- EquiDock: Protein interaction predictions
"With these capabilities," said Nvidia, "drug discovery teams can easily integrate generative AI into their workflows to better understand and design drug molecules virtually -- and reduce the need for time- and resource-heavy physical experiments."